Skip to main content
Caplight Logo









Orange Biomed

Orange Biomed

Private
SeoulHealthcare & Life Scienceshttps://orangebiomed.com/

Last Round

Series A

Extension

Dec 10, 2024

Total Funding Raised

$3.51M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Orange Biomed is a healthcare technology company that develops portable, microfluidic-based devices for measuring glycated hemoglobin (A1c) levels to improve diabetes management.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Health IoT, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

HbA1c testingpoint-of-care testingmicrofluidicsdiabetes managementmedical deviceat-home testingPOCTdiagnostic hardwaredigital healthremote patient monitoringRPMhealth techdiagnostic equityMEMS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Orange Biomed Comparables

Compare Orange Biomed with similar companies based on industry and business-model similarity.

Orange Biomed comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sinocare Inc.
74%
Danaher Corporation
73%
AstraZeneca
73%

Orange Biomed Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionDec 10, 2024
Early FundingAug 10, 2022

Orange Biomed Investors

Notable investors and investment history

Orange Biomed investors
InvestorRounds
K2 Investment PartnersSeries A Extension
Digital Healthcare PartnersEarly Funding
디지털 헬스케어 파트너스Early Funding
Seoul New Technology Investment Co.Early Funding
Intops InvestmentEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors grew 307% MoM to 3.2K.

  • Nov 10, 2025

    Will attend MEDICA 2025 to showcase A1C test.

Orange Biomed Filings

Explore SEC and related filing metadata, where available.

Orange Biomed filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Orange Biomed's valuation, stock price, and market status.

Is Orange Biomed a public or private company?

Orange Biomed is a private company.

What is the current stock price of Orange Biomed?

Orange Biomed is a private company with no public stock price. No recent secondary market data is available.

How much is Orange Biomed worth (valuation)?

Valuation information for Orange Biomed is not publicly available.

Can I buy Orange Biomed stock?

Orange Biomed shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Orange Biomed's last funding round?

Orange Biomed's most recent funding round was Series A Extension on December 10, 2024.

Who are the main investors in Orange Biomed?

Key investors in Orange Biomed include K2 Investment Partners, Digital Healthcare Partners, Seoul New Technology Investment Co., Intops Investment.

Will Orange Biomed IPO soon?

No public IPO plans have been announced for Orange Biomed.

How can I track Orange Biomed secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Orange Biomed's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSeoul
Employee Range8
Year Founded2021
Last FundingDec 10, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?